Last reviewed · How we verify
Auvelity
At a glance
| Generic name | Auvelity |
|---|---|
| Sponsor | Virginia Commonwealth University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] . AUVELITY is not approved for use in pediatric patients [see Use in Specific Populations (8.4)] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing infor
Common side effects
- Dizziness
- Headache
- Diarrhea
- Somnolence
- Dry mouth
- Sexual dysfunction
- Hyperhidrosis
- Anxiety
- Nausea
- Vomiting
- Nervousness
- Restlessness
Serious adverse events
- Pulmonary embolism
- Gastrointestinal hemorrhage
- Intestinal perforation
- Pancreatitis
- Hepatitis
- Complete atrioventricular block
- Brugada pattern/syndrome
- Hypertension (severe)
- Pancytopenia
- Thrombocytopenia
Key clinical trials
- Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |